RECEIVED
CENTRAL FAX CENTER
AUG 0 1 2006

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claims 1-19 (canceled)

Claim 20 (Currently Amended) A hydrophilic controlled release solid oral formulation comprising pregelatinized starch, 9-hydroxyrisperidone, a pharmaceutically acceptable acid addition salt thereof, an N-oxide form thereof, or a stereochemically isomeric form thereof, and one or more viscous hydrophilic polymers wherein the pregelatinized starch enables the formulation to maintain a controlled release of the 9-hydroxyrisperidone in a release media with changing ionic strength.

Claim 21 (Currently Amended) The controlled release solid oral formulation of claim 20, wherein said one or more hydrophilic polymers are selected from the group consisting of alkylcellulose, hydroxyalkylcellulose, hydroxyalkylalkylcellulose, carboxyalkylcellulose, alkali metal salts of carboxyalkylcellulose, natural, semi-synthetic or synthetic polysaccharide, polyacrylic acid and salts thereof, polymethacrylic acid and the salts thereof, polyvinyl alcohol, polyvinylpyrrolidone, and polyalkylene oxides.

Claim 22 (Currently Amended) The controlled release solid oral formulation of claim 20, wherein said one or more hydrophilic polymers are selected from the group consisting of hydroxypropyl cellulose and hydroxypropylmethylcellulose.

Claim 23 (Currently Amended) The controlled release solid oral formulation of claim 22, wherein said hydroxypropylmethylcellulose has a viscosity in a range from about 3,500 mPa.s to about 100,000 mPa.s.

Claim 24 (Currently Amended) The controlled release solid oral formulation of claim 22, wherein said hydroxypropylcellulose has a viscosity of less than about 1,500 mPa.s.

Claim 25 (Currently Amended) The controlled release solid oral formulation of claim 20, wherein said one or more hydrophilic polymers are present in an amount from about 0.01 to about 80 % by weight.

Claim 26 (Currently Amended) The controlled release solid oral formulation of claim 20, wherein at least two hydrophilic polymers are present in said formulation.

Claim 27 (Currently Amended) The controlled release solid oral formulation of claim 26, wherein said at least two hydrophilic polymers are hydroxypropylcellulose and hydroxypropylmethylcellulose.

Claim 28 (Currently Amended) The controlled release solid oral formulation of claim 27, wherein a ratio of said hydroxypropylcellulose to said hydroxypropylmethylcellulose ranges from 1:5 to 5:1.

Claim 29 (Canceled).

Claim 30 (Currently Amended) The controlled release solid oral formulation of claim 1 ~~29~~, wherein said pregelatinized starch is present at about 0.01 – 15 % by weight.

Claim 31 (Currently Amended) The controlled release solid oral formulation of claim 20 further comprising cyclodextrin or a derivative thereof.

Claim 32 (Currently Amended) A method of providing controlled release of 9-hydroxyrisperidone, a pharmaceutically acceptable acid addition salt thereof, an N-oxide form thereof, or a stereochemically isomeric form thereof in a subject, comprising administering the controlled release solid oral formulation of claim 20 to said subject.

Claim 33 (Currently Amended) A method of preparing a controlled release solid oral formulation comprising a step of mixing hydroxyrisperidone, a pharmaceutically acceptable

acid addition salt thereof, an N-oxide form thereof, or a stereochemically isomeric form thereof, with pregelatinized starch and one or more hydrophilic polymers.

Claim 34 (Currently Amended) A controlled release solid oral formulation comprising 9-hydroxyrisperidone, a pharmaceutically acceptable acid addition salt thereof, an N-oxide form thereof, or a stereochemically isomeric form thereof, pregelatinized starch in an amount sufficient to maintain a controlled release of the 9-hydroxyrisperidone in a release media with changing ionic strength, and one or more hydrophilic polymers in a dosage form.